This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Thrombolysis  • Neurology  • Cerebrovascular Disease  • Stroke  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

The CREATE Trial Group Investigators*

JAMA. 2005;293:427-435.

Context  Although reperfusion therapy, aspirin, -blockers, and angiotensin-converting enzyme inhibitors reduce mortality when used early in patients with acute myocardial infarction (MI), mortality and morbidity remain high. No antithrombotic or newer antiplatelet drug has been shown to reduce mortality in acute MI.

Objective  To evaluate the effects of reviparin, a low-molecular-weight heparin, when initiated early and given for 7 days in addition to usual therapy on the primary composite outcome of death, myocardial reinfarction, or strokes at 7 and 30 days.

Design, Setting, and Patients  A randomized, double-blind, placebo-controlled trial (Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation [CREATE]) of 15 570 patients with ST-segment elevation or new left bundle-branch block, presenting within 12 hours of symptom onset at 341 hospitals in India and China from July 2001 through July 2004.

Intervention  Reviparin or placebo subcutaneously twice daily for 7 days.

Main Outcome Measure  Primary composite outcome of death, myocardial reinfarction, or stroke at 7 and 30 days.

Results  The primary composite outcome was significantly reduced from 854 (11.0%) of 7790 patients in the placebo group to 745 (9.6%) of 7780 in the reviparin group (hazard ratio [HR], 0.87; 95% CI, 0.79-0.96; P = .005). These benefits persisted at 30 days (1056 [13.6%] vs 921 [11.8%] patients; HR, 0.87; 95% CI, 0.79-0.95; P = .001) with significant reductions in 30-day mortality (877 [11.3%] vs 766 [9.8%]; HR, 0.87; 95% CI, 0.79-0.96; P = .005) and reinfarction (199 [2.6%] vs 154 [2.0%]; HR, 0.77; 95% CI, 0.62-0.95; P = .01), and no significant differences in strokes (64 [0.8%] vs 80 [1.0%]; P = .19). Reviparin treatment was significantly better when it was initiated very early after symptom onset at 7 days (<2 hours: HR, 0.70; 95% CI, 0.52-0.96; P = .03; 30/1000 events prevented; 2 to <4 hours: HR, 0.81; 95% CI, 0.67-0.98; P = .03; 21/1000 events prevented; 4 to <8 hours: HR, 0.85; 95% CI, 0.73-0.99; P = .05; 16/1000 events prevented; and 8 hours: HR, 1.06; 95% CI, 0.86-1.30; P = .58; P = .04 for trend). There was an increase in life-threatening bleeding at 7 days with reviparin and placebo (17 [0.2%] vs 7 [0.1%], respectively; P = .07), but the absolute excess was small (1 more per 1000) vs reductions in the primary outcome (18 fewer per 1000) or mortality (15 fewer per 1000).

Conclusions  In patients with acute ST-segment elevation or new left bundle-branch block MI, reviparin reduces mortality and reinfarction, without a substantive increase in overall stroke rates. There is a small absolute excess of life-threatening bleeding but the benefits outweigh the risks.

*Authors/Writing Committee: Salim Yusuf, DPhil, Shamir R. Mehta, MD, MSc, Changchun Xie, PhD, Rashid J. Ahmed, BScH (Population Health Research Institute, Hamilton Health Sciences, and McMaster University, Hamilton, Ontario); Denis Xavier, MD, Prem Pais, MD (Institute of Population Health and Clinical Research, St John’s National Academy of Health Sciences, Bangalore, India); Jun Zhu, MD, Lisheng Liu, MD (Cardiovascular Institute and Fu Wai Hospital, Chinese Hypertension League Institute, Beijing, China).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Reviparin in Acute Myocardial Infarction
Francesco Buccelletti
JAMA. 2005;293(21):2595.
EXTRACT | FULL TEXT  

Reviparin in Acute Myocardial Infarction
Andrew T. Yan, Raymond T. Yan, and Shaun G. Goodman
JAMA. 2005;293(21):2595.
EXTRACT | FULL TEXT  

Reviparin in Acute Myocardial Infarction—Reply
Salim Yusuf, Chanchun Xie, and Janice Pogue
JAMA. 2005;293(21):2595-2596.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial
The CREATE-ECLA Trial Group Investigators*
JAMA. 2005;293(4):437-446.
ABSTRACT | FULL TEXT  

Simple Principles of Clinical Trials Remain Powerful
Robert M. Califf
JAMA. 2005;293(4):489-491.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acute Coronary Syndromes: Diagnosis and Management, Part II
Kumar and Cannon
Mayo Clin Proc. 2009;84:1021-1036.
ABSTRACT | FULL TEXT  

Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs
Pogue et al.
Clin Trials 2009;6:239-251.
ABSTRACT  

Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Potsis et al.
ANGIOLOGY 2009;60:148-158.
ABSTRACT  

Anticoagulation for ST-Segment Elevation Myocardial Infarction
Eikelboom and Weitz
Circulation 2009;119:1186-1188.
FULL TEXT  

ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
Bhatt et al.
J Am Coll Cardiol 2008;52:1502-1517.
FULL TEXT  

ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
Writing Committee Members et al.
Circulation 2008;118:1894-1909.
FULL TEXT  

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT | FULL TEXT  

Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Goodman et al.
Chest 2008;133:708S-775S.
ABSTRACT | FULL TEXT  

The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial
Peters et al.
Eur Heart J 2008;29:324-331.
ABSTRACT | FULL TEXT  

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment
Oldgren et al.
Eur Heart J 2008;29:315-323.
ABSTRACT | FULL TEXT  

2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:210-247.
FULL TEXT  

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:172-209.
FULL TEXT  

2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee
Antman et al.
Circulation 2008;117:296-329.
FULL TEXT  

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
King et al.
Circulation 2008;117:261-295.
FULL TEXT  

Enoxaparin and ST-elevation myocardial infarction: reply
Giraldez and Antman
Eur Heart J 2007;28:2952-2953.
FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction
Diaz et al.
JAMA 2007;298:2399-2405.
ABSTRACT | FULL TEXT  

Perspectives on the management of coronary artery disease in India
Karthikeyan et al.
Heart 2007;93:1334-1338.
ABSTRACT | FULL TEXT  

Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
Murphy et al.
Eur Heart J 2007;28:2077-2086.
ABSTRACT | FULL TEXT  

Beyond Unfractionated Heparin and Warfarin: Current and Future Advances
Hirsh et al.
Circulation 2007;116:552-560.
FULL TEXT  

Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis
Giraldez et al.
Eur Heart J 2007;28:1566-1573.
ABSTRACT | FULL TEXT  

Women, Acute Ischemic Heart Disease, and Antithrombotic Therapy: Challenges and Opportunities
Harrington
Circulation 2007;115:2796-2798.
FULL TEXT  

Anticoagulants in heart disease: current status and perspectives
De Caterina et al.
Eur Heart J 2007;0:ehl492v1-34.
FULL TEXT  

Update in cardiology.
Rapaport
ANN INTERN MED 2006;145:618-625.
FULL TEXT  

Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease.
Coca et al.
JAMA 2006;296:1377-1384.
ABSTRACT | FULL TEXT  

Fondaparinux in ST-Segment Elevation Myocardial Infarction: The Drug, the Strategy, the Environment, or All of the Above?
Califf
JAMA 2006;295:1579-1580.
FULL TEXT  

Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial
The OASIS-6 Trial Group*
JAMA 2006;295:1519-1530.
ABSTRACT | FULL TEXT  

Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials
Eikelboom et al.
Circulation 2005;112:3855-3867.
ABSTRACT | FULL TEXT  

Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit
Rothberg et al.
ANN INTERN MED 2005;143:241-250.
ABSTRACT | FULL TEXT  

Additional articles abstracted in ACP Journal Club
Evid. Based Med. 2005;10:126-126.
FULL TEXT  

Rescuing COX-2 Inhibitors From the Waste Bin
Albini and Noonan
JNCI J Natl Cancer Inst 2005;97:859-860.
FULL TEXT  

Reviparin in Acute Myocardial Infarction
Buccelletti
JAMA 2005;293:2595-2595.
FULL TEXT  

Reviparin in Acute Myocardial Infarction
Yan et al.
JAMA 2005;293:2595-2595.
FULL TEXT  

Does Reviparin Improve Outcomes in STEMI?
JWatch Emergency Med. 2005;2005:3-3.
FULL TEXT  

LMWH Improves Post-STEMI Outcomes
Journal Watch Cardiology 2005;2005:1-1.
FULL TEXT  

Low-Molecular-Weight Heparin After Myocardial Infarction
JWatch General 2005;2005:2-2.
FULL TEXT  

Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial
The CREATE-ECLA Trial Group Investigators*
JAMA 2005;293:437-446.
ABSTRACT | FULL TEXT  

Simple Principles of Clinical Trials Remain Powerful
Califf
JAMA 2005;293:489-491.
FULL TEXT